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Abstract
IL-17 is a pro-inflammatory cytokine implicated in autoimmune and inflammatory conditions. The development/survival of
IL-17-producing CD4 T cells (Th17) share critical cues with B-cell differentiation and the circulating follicular T helper subset
was recently shown to be enriched in Th17 cells able to help B-cell differentiation. We investigated a putative link between
Th17-cell homeostasis and B cells by studying the Th17-cell compartment in primary B-cell immunodeficiencies. Common
Variable Immunodeficiency Disorders (CVID), defined by defects in B-cell differentiation into plasma and memory B cells, are
frequently associated with autoimmune and inflammatory manifestations but we found no relationship between these and
Th17-cell frequency. In fact, CVID patients showed a decrease in Th17-cell frequency in parallel with the expansion of
activated non-differentiated B cells (CD21lowCD38low). Moreover, Congenital Agammaglobulinemia patients, lacking B cells
due to impaired early B-cell development, had a severe reduction of circulating Th17 cells. Finally, we found a direct
correlation in healthy individuals between circulating Th17-cell frequency and both switched-memory B cells and serum
BAFF levels, a crucial cytokine for B-cell survival. Overall, our data support a relationship between Th17-cell homeostasis and
B-cell maturation, with implications for the understanding of the pathogenesis of inflammatory/autoimmune diseases and
the physiology of B-cell depleting therapies.
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Introduction
CD4 T cells with the ability to produce the pro-inflammatory
cytokine interleukin (IL)-17, designated Th17 [1,2,3], act as co-
ordinators of the innate and adaptive immune responses to bacteria
and fungi, in particular Candida albicans [4], and have been implicated in
several autoimmune diseases, such as multiple sclerosis, rheumatoid
arthritis, systemic lupus erythematosus, psoriasis and Crohn’s disease
[5]. Common Variable Immunodeficiency Disorders (CVID) are
defined by impaired antibody production and frequently associate with
autoimmune and inflammatory manifestations [6,7,8,9]. It is thus
plausible that IL-17 may play a role in these processes.
The defects in mature B-cell development that characterize
CVID mainly result in impaired organization of germinal centres
(GC) [10], specialized structures within follicles where antigen-
driven somatic hypermutation and class switch recombination
occur, and thus the main source of switched-memory B cells and
plasma cells [11]. Several molecular cues that are essential for B-
cell differentiation in GCs are also required or may contribute to
the induction and/or survival of Th17 cells. IL-6, a major factor
for the differentiation of naive CD4 T cells into Th17 cells [3], also
plays a key role in B-cell proliferation and antibody secretion [12].
IL-21 was first described as having a critical role in the regulation
of antibody production by B cells [13,14], and was later shown to
be involved in Th17-cell differentiation [15,16]. Furthermore, IL-
21 is abundantly produced by Th17 cells and plays an important
autocrine role in their differentiation and maintenance [4]. Several
co-stimulatory molecules have also been shown to play roles in
both Th17 induction and/or survival as well as in B-cell
differentiation into plasma and memory B cells, namely ICOS
and CD40L [17,18,19,20,21,22]. T-cell help is known to be
fundamental to the induction and subsequent organization of
GCs, enabling an adequate generation of plasma and memory B
cells. This help is a characteristic of a particular subset of T cells,
follicular helper T cells (TFH), identifiable by the expression of the
chemokine receptor CXCR5, which is essential for their specific
homing to follicles in lymphoid tissues, and by the production of
IL-21 [23]. Although TFH cells reside mainly within follicles and
GCs, a population of circulating TFH cells has been consistently
observed in humans [24,25]. This circulating TFH subset has been
recently demonstrated to be a counterpart for TFH cells found in
GCs [26], and to be enriched not only in Th2 but also in Th17
cells that are able to help B-cell differentiation [26].
We hypothesized that the homeostasis of the circulating Th17
compartment may be related to B-cell differentiation. Confirming
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such a relationship would have major clinical implications, given
the increasing use of B-cell depleting therapies in many
autoimmune and lymphoproliferative diseases. As a strategy to
investigate the contribution of B cells to the Th17 subset, we
studied this population in CVID patients as well as in patients
lacking B cells due to Congenital Agammaglobulinemia. This
latter condition is associated with impaired early B-cell develop-
ment in the bone marrow as a result, in the majority of cases, of
mutations in the Bruton’s tyrosine kinase gene, usually leading to a
complete lack of circulating B cells [27]. The evaluation of these
primary B-cell deficiencies combined with the study of healthy
individuals supports a link between the homeostasis of the
circulating Th17-cell pool and B-cell differentiation.
Materials and Methods
Ethics Statement
All subjects gave written informed consent for blood sampling
and processing. The study was approved by the Ethical Board of
the Faculty of Medicine of Lisbon.
Participants
The study involved 30 healthy individuals, 31 patients with
CVID, and 6 patients with Congenital Agammaglobulinemia. The
clinical-epidemiological data of the three groups are summarized
in Table 1. CVID patients were diagnosed according to the
European Society for Immunodeficiency criteria (www.esid.org),
namely decreased serum IgG as well as IgM and/or IgA levels at
least 2 SD below the mean for age, impaired antibody response to
vaccines, absent/low isohemagglutinins, and exclusion of defined
causes of hypogammaglobulinemia. The 31 CVID patients were
not related, with the exception of two homozygous twins. All the
patients with Congenital Agammaglobulinemia had less than 1%
B cells within total peripheral lymphocytes. 29 CVID and all
Congenital Agammaglobulinemia patients were under IgG
replacement therapy, adjusted to guarantee pre-infusion Ig levels
above 650 mg/dL. The two CVID patients not receiving IgG had
levels of total serum IgG of 227 and 473 mg/dL.
Monoclonal antibodies used in flow cytometry
The following anti-human monoclonal antibodies were used,
with clone and the directly conjugated fluorochrome specified in
brackets: CD3 (SK7; peridinin chlorophyll protein (PerCP)), CD4
(SK3; PerCP), CD8 (SK1; PerCP and allophycocyanin (APC)-
Cy7; RPA-T8; APC), CCR6 (11A9; phycoerythrin (PE)), CD38
(HB7; PE), CD45RA (L48; PE-Cy7), IgD (IA6-2; PE), IgM (G20-
127; APC), HLA-DR (L243; fluorescein isothiocyanate (FITC)),
IFN-c (4S.B3; FITC), IL-2 (MQ1-17H12; PE), IL-4 (MP4-25D2;
PE), from BD Biosciences, San Jose, CA; CD3 (UCHT1; APC-
eFluor780), CD4 (RPA-T4, FITC, PerCP-Cy5.5 and PE-Cy7),
CD8 (RPA-T8; FITC and PE), CD19 (HIB19; PerCP-Cy5.5 and
PE-Cy7), CD27 (O323; FITC, PE, APC and PE-Cy7), CD45RO
(UCHL1; PE), CD69 (FN50; FITC), CD45RA (HI100; FITC and
APC), IL-17A (eBio64DEC17; PerCP-Cy5.5 and Alexa Fluor
647), TNF-a (MAb11; PE), from eBiosciences, San Diego, CA;
CD4 (S3.5; PE) from Caltag, Buckingham, UK; CCR7 (150503;
FITC), CXCR5 (51505.111; PE), from R&D Systems, Minneap-
olis, MN; CD21 (BL13; FITC) from IO Test, Beckman Coulter,
Brea, CA.
Cell staining and flow cytometric analysis
Phenotypic analysis was performed in whole blood samples
collected immediately before IgG administration, after staining
with monoclonal antibodies and red blood cells lysis using BD
FACS Lysing Solution (BD Biosciences). Samples were acquired
on a FACSCalibur or on a FACSCanto flow cytometer (BD
Biosciences). A minimum of 100,000 lymphocytes were acquired
per sample. Data were analysed using CellQuest Software (BD
Biosciences) and FlowJo Software (Tree Star Inc., Ashland, OR).
Total cell numbers were calculated by multiplying the percentage
of each population within total lymphocytes by the peripheral
blood lymphocyte count obtained at the clinical laboratory on the
day of sampling.
Analysis of cytokine production
Freshly isolated peripheral blood mononuclear cells (PBMC) by
Ficoll-Hypaque density gradient (Amersham Pharmacia Biotech,
Uppsala, Sweden) were assessed for cytokine production at the
single-cell level, as previously described [28]. Briefly, after a 4-hour
culture with phorbol myristate acetate (PMA) (50 ng/mL, Sigma-
Aldrich) plus ionomycin (500 ng/mL; Calbiochem, Merck Biosci-
ences, Nottingham, U.K.), in the presence of brefeldin A (10 mg/
mL; Sigma-Aldrich), PBMC were surface stained and then fixed
(2% formaldehyde; Sigma-Aldrich, St Louis, MO), permeabilized
(phosphate buffered saline/1% bovine serum albumin/0.5%
saponin) (Sigma-Aldrich) and stained intracellularly with mono-
clonal antibodies against IL-2, IL-4, IFN-c, TNF-a and IL-17.
Table 1. Clinical and epidemiological data of the cohorts
studied.
Healthy CVID
Congenital
Agammaglobulinemiaa
Number (male/female) 30 (9/21)d 31 (11/20) 6 (6/0)
Age (yrs.) 41615d 40613 2465
Clinical
manifestationsb,c
Autoimmune disease n.a. 17/31 (55%) 0
Adenopathies n.a. 10/31 (32%) 0
Lymphoid proliferation n.a. 18/20e (86%) 0
Granulomas n.a. 3/20e (15%) 0
Chronic diarrhoea n.a. 15/31 (48%) 0
Splenomegaly n.a. 16/31 (52%) 0
IgG replacement
therapyc
intravenous n.a. 24/31 (77%) 6 (100%)
subcutaneous n.a. 5/31 (16%) 0
Length of IgG
therapy (yrs.)
n.a. 766 1569
n.a. not applicable, CVID: Common Variable Immunodeficiency Disorders.
aGenetic defects in the Btk gene were identified in 4 of the congenital
agammaglobulinemia patients, namely IVS17-1GRC, R288Q, IVS8-2ARG, and
Y375X mutations; in the other 2 patients, Btk mutations have been excluded
and other genes are currently being evaluated.
bDiagnostic criteria: Autoimmune disease - clinical data, given the impairment
in Ab production; Adenopathies - lymph node larger than 1 cm diameter in 2
or more lymphatic chains in clinical and/or imaging exams; Lymphoid
proliferation and Granulomas - diffuse lymphocytic infiltrates or granulomas
on gastrointestinal, lymph node or pulmonary biopsies; Splenomegaly -
longitudinal spleen diameter superior to 15 cm (computed tomography or
ultrasonography).
cPercentage within total cohort evaluated in brackets.
d15/30 healthy subjects were included in detailed immunological studies (10
female; age 39611 years).
eTotal number of individuals with biopsies.
doi:10.1371/journal.pone.0022848.t001
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Flow cytometric analysis was subsequently performed as described
above.
Quantification of serum levels of BAFF
Serum concentrations of BAFF (BlyS/TNFSF13B; B-cell
activating factor) were quantified by Enzyme Linked Immunosor-
bent Assay (ELISA) using the BAFF Immunoassay Kit (R&D
Systems), according to the manufacturer’s instructions.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 5.0 (GraphPad Software Inc, SD). Two group comparisons
were performed using Mann-Whitney test. Spearman’s coefficient
was used to determine the significance of the correlation between
two variables. Results are expressed as mean6SEM, and P-
values,0.05 were considered to be significant.
Results
Th17 cells in patients with CVID
We evaluated, for the first time, the frequency of circulating
Th17 cells in CVID. Our CVID cohort (Table 1) featured the
characteristic impairment of GC organization and generation of
B-cell memory, demonstrated by the striking decrease in the
frequency of switched-memory B cells, accumulation of
CD38hiIgMhi transitional B cells, and expansion of CD21lowC-
D38low B cells, a population believed to be related to continuous
B-cell activation in the presence of impaired GC function [29,30]
(Figure S1A and S1B). No association was observed between the
frequency of Th17 cells and transitional B cells, a pre-GC B-cell
population (Figure 1A). In contrast, we found a statistically
significant negative correlation between Th17 cells and
CD21lowCD38low B cells, in CVID patients (Figure 1A), suggesting
a decline in the frequency of circulating Th17 cells that matched
the B-cell disturbances indicative of GC disruption. The fact that
we did not observe a relationship with the frequency of switched-
memory B cells is likely related to the heterogeneity of blocks in
GC differentiation that CVID patients present [10]. Our CVID
cohort presented an unusually high proportion of autoimmune
and lymphoproliferative manifestations (Table 1), possibly related
to a reference bias associated with an immunology department in a
central hospital. We next assessed whether these inflammatory and
autoimmune manifestations could be related to an expansion of
Th17 cells, as reported in other autoimmune settings [5]. We
found no increase in the frequency of Th17 cells in CVID patients
with autoimmunity (Figure 1B), even when CVID patients were
split according to the type of autoimmune manifestation, namely
autoimmune cytopenias and organ specific autoimmunity (data
not shown). In contrast, the CD21lowCD38low B-cell subset was
significantly expanded in the subgroup of CVID patients with
autoimmunity (Figure S1C).
CVID patients have been classified according to the previously
mentioned B-cell sub-populations [9]. The stratification of our
CVID cohort according to the EUROclass classification [9]
revealed that a statistically significant decrease in Th17 frequency
was restricted to the group with less than 2% switched-memory B
cells and more than 10% CD21lowCD38low B cells (Figure 1C), in
agreement with the above results.
Several T-cell imbalances were also observed in the CVID
cohort, as previously reported [31], namely an expansion of
effector-memory T cells, increased production of the pro-
inflammatory cytokines interferon (IFN)-c and tumour necrosis
factor (TNF)-a, and up-regulation of activation markers within
both CD4 and CD8 T cells (Figure S2). Of note, the frequency of
Th17 cells was found to negatively correlate with CD4 T-cell
activation in CVID patients (Figure 1D), with no relationship with
naı¨ve/memory T-cell imbalances (correlation with the frequency
of naı¨ve cells within CD4 T cells, r = 0.3065, P = .1058). In
contrast, the frequency of IFN-c-producing cells was found to
negatively correlate with naı¨ve CD4 T cells (r =20.8199,
P,.0001) and positively with the levels of CD4 T-cell activation
in CVID patients (r = 0.6098, P = .0003). Similar relationships
were observed with the expression levels of activation markers
within the CD8 T-cell subset (data not shown). We also
investigated whether the increased production of IFN-c observed
in CVID patients had an impact on the concomitant production of
this cytokine by Th17 cells. We found no significant differences in
the proportion of IFN-c+ cells within the IL-17-producing CD4
subset as compared to healthy subjects (22.55%62.34% in CVID
and 14.45%61.70% in healthy, P = .0567) and no relationship
between the frequencies of IFN-c- and IL-17-producing CD4 T
cells (r =20.2504, P = .1821). Moreover, in contrast to IFN-c-
producing CD4 T cells, no association was found between the
frequency of IL-17+IFN-c+ CD4 T cells and the naı¨ve/memory
imbalances (P..1500).
In conclusion, no association between Th17 cells and
autoimmune manifestations or production of other pro-inflamma-
tory cytokines was observed in CVID patients. The levels of Th17
cells were apparently more directly related to B-cell differentiation
than to T-cell disturbances, showing a negative correlation with
the pathological expansion of a B-cell population associated with
impaired GC function (CD21lowCD38low B cells) in CVID.
Decreased frequency of Th17 cells in individuals without
B cells
In order to further investigate the relationship between B cells
and the IL-17-producing CD4 subset, we evaluated this popula-
tion in individuals with Congenital Agammaglobulinemia, who
lack mature B cells due to genetic defects impairing early B-cell
development [27] (Table 1). A marked reduction in the frequency
of Th17 cells was found in these patients (Figure 2A and 2B).
In spite of the reduced Th17 frequency, these patients do not
exhibit a major increase in the frequency of infections with Candida
albicans, which may be related to the preservation of innate sources
of IL-17, such as cd T cells, natural killer T cells or myeloid cells.
Of note, these individuals featured neither significant naı¨ve T-
cell imbalances, nor major alterations in the levels of T-cell
activation nor frequencies of IFN-c-, TNF-a-, IL-2- or IL-4-
producing cells, as compared to healthy subjects (Figure S2).
Importantly, a significant reduction of circulating TFH cells was
found in these patients (Figure 2B), likely related to decreased GC
generation in the context of Congenital Agammaglobulinemia, as
recently reported [32]. A decrease in this circulating CD4 T-cell
population has also been described in the context of human ICOS-
deficiency, a situation in which the generation of GCs is known to
be severely perturbed [33].
In conclusion, we report here a major reduction in the Th17-
cell pool in patients lacking B cells.
Direct correlation between the frequency of circulating
Th17 cells and switched-memory B cells in healthy
individuals
Our findings suggesting a relationship between the homeostasis
of the circulating Th17 compartment and B-cell disturbances led
us to investigate this putative relationship in healthy individuals.
We found a direct correlation between the frequency of CD4 T
cells able to produce IL-17 and the frequency of B cells exhibiting
Human Th17 Homeostasis and Memory B Cells
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22848
a switched-memory phenotype in these individuals (Figure 3). This
relationship was also observed when absolute numbers of the
circulating populations were considered (r = 0.4565, P = .0249).
In addition, healthy individuals exhibited a negative correlation
between the frequency of Th17 cells and the serum levels of B-cell
activating factor (BAFF) (Figure 4A), a critical cytokine for B-cell
differentiation and survival [34]. In contrast, we did not observe
any relationship between BAFF serum levels and the production of
other pro-inflammatory cytokines, such as IFN-c and TNF-a, or
IL-4 (data not shown), thus highlighting the specificity of the link
to Th17 cells. These results are in conformity with our previous
observation of a relationship between IL-17 production by CD4 T
cells and B-cell maturation in the context of primary B-cell
deficiencies.
It has recently been demonstrated in mice that local BAFF-gene
targeting in dendritic cells suppressed both the generation of
plasma cells and Th17 cells [35], suggesting that BAFF promotes
Th17-cell proliferation and expansion, possibly through the
modulation of the cytokine milieu. However, providing our
finding of a negative association between BAFF and IL-17 we
hypothesize that BAFF effects may be indirectly mediated by the
B-cell subset. In order to further investigate this possibility we
quantified serum BAFF levels in the CVID and Congenital
Agammaglobulinemia cohorts. In agreement with recent reports
[36,37], serum BAFF levels were significantly increased in CVID
patients, and were even higher in Congenital Agammaglobulin-
emia, reaching statistical significance in comparison to both
healthy individuals and to CVID patients (Figure 4B). However,
no correlation was found between BAFF serum levels and the
frequency of Th17 cells in CVID and Congenital Agammaglob-
ulinemia patients (Figure 4C). Notably, in the absence of B cells as
illustrated by Congenital Agammaglobulinemia patients, very high
levels of BAFF may be associated with very low frequencies of
Th17 cells (Figure 4C), not supporting a direct role of BAFF in the
induction/survival of Th17 cells. Overall, our data suggest that the
association between IL-17-producing CD4 T cells and BAFF is
likely related to its effects on B cells.
Discussion
We report here an association between the frequencies of Th17
cells and switched-memory B cells in healthy individuals, and a
marked reduction of this CD4 subset in patients with congenital
absence of peripheral B cells. Additionally, in patients with
Figure 1. Th17 cells in patients with CVID. (A) Correlation between Th17 frequency and frequency of switched-memory B cells (left), transitional
B cells (middle) or CD21low B cells (right), in CVID patients. Switched-memory B cells were defined as CD27+ IgD2 cells, transitional B cells as CD38high
IgMhigh cells and CD21low B cells were defined as CD21low CD38low cells within gated B cells (CD19+) after surface staining of whole blood samples. IL-
17 expression was assessed at the single-cell level by intracellular staining following short-term stimulation of PBMC with PMA and ionomycin. (B)
Th17 frequency in CVID individuals stratified according to their clinical manifestations, namely autoimmunity, lymphoid proliferation, splenomegaly,
and adenopathies. (C) Th17 frequency in healthy controls and CVID patients grouped according to EUROclass. (D) Correlations between frequencies
of activated CD4 T cells, defined by concurrent expression of HLA-DR and CD38, and of Th17 cells in CVID and healthy individuals. Each symbol
represents one individual. Bars represent mean. Data were compared using Mann-Whitney test, and P values are shown. Correlation significance was
assessed using Spearman coefficient test, and r and P values are shown.
doi:10.1371/journal.pone.0022848.g001
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primary defects in mature B-cell differentiation, the frequency of
Th17 cells was inversely correlated with markers of GC
impairment, further supporting the link between B cells and the
differentiation or maintenance of Th17 cells.
Our data generated in human B-cell deficiencies suggest, for the
first time, that B cells play a role in the homeostasis of the Th17
subset. On the other hand, several previous reports have
implicated IL-17 in B-cell differentiation and function. A recent
report [38] suggested that IL-17 and possibly Th17 cells can
contribute to GC function in general. This work using BXD2
mice, which develop spontaneous erosive arthritis associated with
auto-antibody production, showed that the enhanced somatic
hypermutation and class-switch recombination found in these
animals resulted from the direct action of IL-17 on B cells, leading
to increased frequency and duration of GCs [38]. Recent data
from human studies also suggest that Th17 cells may contribute to
the generation of ectopic GCs within kidney allografts through the
production of IL-21 [39], further establishing a link between IL-17
and B-cell function. Importantly, IL-17 alone has been described
to promote human B-cell survival and to synergize with BAFF to
induce B-cell proliferation and differentiation into antibody-
secreting plasma cells [40]. Recent reports have, in this sense,
established a direct impact of IL-17 on B cells [38,40], with respect
to proliferation, survival and antibody production, and have
shown that Th17 cells can act as B-cell helpers [41]. Our
observation of markedly reduced levels of Th17 cells in the
absence of other major T-cell imbalances in patients with
congenital absence of B cells suggests an important contribution
Figure 2. Decreased frequency of Th17 cells in individuals lacking B cells. (A) Representative dot-plots of the analysis of IFN-c and IL-17
production by CD4 T cells, determined by intracellular staining, for a healthy individual (left), a CVID patient (middle) and a Congenital
Agammaglobulinemia (Agamma) patient (right). Numbers inside dot-plots represent the proportion of cells expressing the markers. (B) Frequency of
Th17 cells (left) and CXCR5+ CD4 T cells (right) in healthy individuals and Congenital Agammaglobulinemia patients (Agamma). Each symbol
represents one individual. Bars represent mean. Data were compared using Mann-Whitney test, and P values are shown.
doi:10.1371/journal.pone.0022848.g002
Human Th17 Homeostasis and Memory B Cells
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e22848
of B cells to the homeostasis of Th17 cells. Although the number of
patients with this rare immunodeficiency under follow-up is small,
the remarkable consistency of the results generated in these
patients strengthens our finding of a reduced Th17 compartment
in Congenital Agammaglobulinemia. Such a relationship was
further supported by the negative correlation between Th17
frequency and the expansion of the CD21lowCD38low B-cell subset
in CVID patients, a pathological B-cell population resulting from
altered B-cell activation associated with defects in GC function
[29,30].
Our results raise the possibility of a follicular contribution to the
maintenance of the Th17-cell subset, a notion further supported
by a recent report [26]. We were able to reveal a fraction of Th17
cells expressing both CXCR5 and CCR7, in addition to CCR6,
likely having the potential to home to follicles (data not shown).
This is particularly relevant given the fact that circulating TFH cells
were reported to be enriched in Th17 cells that are able to help B-
cell differentiation [26]. We have studied this population in
patients without peripheral B cells due to early defects in B-cell
development, which, as described in ICOS-deficient patients
[33,42], are expected to have reduced generation of GCs. We
found the circulating CXCR5+ CD4 T-cell population to be
significantly diminished in these patients, as compared to healthy
subjects, in agreement with a recent report [32], further
supporting the notion of circulating TFH cells being counterparts
of the follicular helper T cells found in GCs. Our results suggest
that the impairment in GC generation may underlie the reduced
frequencies of both TFH and Th17 cells.
Contrary to what we observed in Congenital Agammaglobu-
linemia, CVID patients presented with several T-cell imbalances
[31], namely an increase in the production of the pro-
inflammatory cytokines IFN-c and TNF-a, in direct correlation
with the up-regulation of activation markers. We found that the
Th17-cell population decreased concurrently with the hyper-
activated state, suggesting that a different mechanism is involved in
its regulation in CVID patients. Furthermore, a significant
proportion of our CVID cohort featured autoimmune manifesta-
tions and some patients exhibited inflammatory processes that
shared similarities with the pathology of Crohn’s disease, a
condition in which Th17 cells have been implicated [5,43].
However, in contrast to Crohn’s disease, it has been shown that
CVID patients with symptomatic gut inflammation exhibit a
reduced ability to produce IL-17 and IL-23 by the lamina propria
mononuclear cells, in spite of increased IL-12 and IFN-c secretion
[43]. Importantly, we found no increase in the frequency of CD4
T cells able to produce IL-17 in CVID patients presenting with
autoimmune disease, either with autoimmune cytopenia or other
autoimmune disorders. In fact, an inverse correlation was found
with the expansion of the CD21lowCD38low B-cell subset that has
been implicated in autoimmunity. These findings are particularly
relevant given that our cohort presents an exceptionally high
prevalence of autoimmune manifestations.
A recent report suggested that the commercial immunoglobulin
(Ig) used in intravenous therapy has the ability to inhibit the
differentiation, amplification and function of human Th17 cells in
vitro [44]. However, such an effect is unlikely to account for the
observations described here, since both Congenital Agammaglob-
ulinemia and CVID patients undergo replacement therapy with Ig
(Table 1).
The development and homeostasis of Th17 cells and memory
B cells share several determinants. Tumour growth factor (TGF)-
b has a unique role in driving IgA isotype switching, which is the
major Ig type produced at mucosal sites [45], and is also critical
for Th17-cell differentiation [15,16]. Both IgA and IL-17-
producing CD4 T cells have an important function in the
modulation of gut flora and mucosal immunity [45]. It is thus
plausible that the link between IL-17 production and B-cell
function could mainly lie in the isotype switch to IgA, a notion
further supported by the fact that patients with Congenital
Agammaglobulinemia or CVID have impaired IgA production.
This possibility led us to investigate the frequency of circulating
Th17 cells in patients with selective IgA deficiency. However, no
imbalances in this CD4 subset were found in patients with
undetectable serum levels of IgA as compared to healthy
individuals (data not shown), suggesting that the link between B
cells and IL-17 production is not dependent of the development
of IgA-producing cells. It is unlikely that a unique molecule or
pathway determine the impact of B cells in the homeostasis of the
Th17 subset, being more plausible that several mechanisms are
involved, either through direct interactions or through the
influence of factors modulated by B cells.
BAFF is a crucial survival factor for peripheral B cells. As
expected from previous reports, both CVID and Congenital
Agammaglobulinemia patients presented highly increased serum
levels of this cytokine [36,37]. Although increased BAFF
production by cells of the innate immune system, such as
neutrophils, macrophages, monocytes and dendritic cells, could
be enhanced in these patients, contributing to these increased
levels, it is more likely that they resulted from reduced
consumption of BAFF due to the decreased number of target
cells in both conditions. This latter hypothesis is supported by the
fact that B-cell depletion upon rituximab treatment, a monoclonal
antibody targeting CD20, results in significantly increased levels of
BAFF that return to baseline levels upon B-cell re-population [46].
Thus, high BAFF levels may be considered a measure of B-cell
dysfunction and, in this sense, the negative correlation we report in
healthy individuals between the frequency of Th17 cells and the
serum levels of BAFF further strengthens the link between IL-17
production and B-cell maturation.
Figure 3. Direct correlation between the frequencies of
circulating Th17 cells and switched-memory B cells in healthy
individuals. Correlation between the frequencies of switched-memory
(CD27+IgD2) B cells and Th17 cells in healthy individuals. Each symbol
represents one healthy individual. Correlation significance was assessed
using Spearman coefficient test, and r and P values are shown.
doi:10.1371/journal.pone.0022848.g003
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B cell-depleting therapies have been increasingly used in various
clinical settings, including pathologies where IL-17 has been
implicated [46,47,48]. Additionally, BAFF-targeting therapies
offer a promising approach for autoimmune/inflammatory
disorders [46,48]. Our data raise the possibility that these
treatments may have an impact on Th17 cells and, in this way,
influence the clinical outcome mediated by these therapeutic
strategies. In line with these observations, a very recent report has
shown that rituximab treatment selectively reduces the Th17-cell
response in rheumatoid arthritis patients [49]. Nevertheless, such
an inhibition does not seem to lead to an increased frequency of
mucocutaneous candidiasis in rituximab-treated patients [49], an
infection associated with Th17 deficiency.
In conclusion, our data show, for the first time, that the
induction/proliferation/survival of Th17 cells is related to B-cell
function. These results provide support for a link between Th17 and
B cells that is relevant for the understanding of the pathogenesis of
inflammatory/autoimmune diseases as well as the mechanisms
underlying the effects of therapeutic strategies targeting B cells.
Supporting Information
Figure S1 B-cell disturbances in CVID patients. (A)
Representative plots of the flow cytometry analysis of switched-
memory B cells (top), CD21lowCD38low B cells (middle) and
transitional B cells (bottom), in healthy individuals (left panels) and
CVID patients (right panels). Numbers represent the percentage of
the given population within CD19+ cells. (B) Comparison of the
frequencies of these B-cell subsets in CVID and in healthy
individuals. (C) Frequency of CD21lowCD38low within B cells in
healthy controls and CVID individuals stratified according to their
clinical manifestations, namely autoimmunity, lymphoid prolifer-
ation, splenomegaly, and adenopathies. Each symbol represents
one individual. Bars represent mean. Data were compared using
Mann-Whitney test, and P values are shown.
(TIF)
Figure S2 T-cell disturbances in CVID and Congenital
Agammaglobulinemia patients. Analysis of: (A) frequency
and absolute numbers of naı¨ve (CD45RA+CD27+) within CD4 T
Figure 4. Negative correlation between the frequency of Th17 cells and serum BAFF levels in healthy subjects. (A) Correlation between
the frequency of Th17 cells and serum levels of the cytokine BAFF, as determined by ELISA, in healthy individuals. (B) Analyses of the serum levels of
BAFF in healthy individuals, CVID and Congenital Agammaglobulinemia patients. Each symbol represents one individual. Data were compared using
Mann-Whitney test, and P values are shown. (C) The same correlation described in (A) for CVID patients and Congenital Agammaglobulinemia
patients. Each symbol represents one individual. Correlation significance was determined using Spearman coefficient test, and r and P values are
shown.
doi:10.1371/journal.pone.0022848.g004
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cells; (B) frequency and absolute numbers of naı¨ve
(CD45RA+CD27+) and terminally-differentiated (CD45RA+
CD272) within CD8 T cells; (C) frequency of activated (HLA-
DR+CD38+) within CD4 T cells and CD8 T cells; and (D)
frequencies of IFN-c-, TNF-a-, IL-4-, and IL-2-producing CD4 T
cells assessed at the single-cell level by intracellular staining
following short-term PBMC stimulation with PMA and ionomy-
cin. Bars represent mean6SEM. Data were compared using
Mann-Whitney test, and P values are shown.
(TIF)
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